GlassScriptPhysician profile
Michael Jay Mellman
NPI 1184732489
$17,307.12
in general payments reported to CMS, 2019-2025
52 companies · $2,222 in 2025
The $2,222 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,738 · 2020: $2,496 · 2021: $2,831 · 2022: $2,720 · 2023: $2,134 · 2024: $2,167 · 2025: $2,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,495 · Education: $27.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,494.70 |
| Education | $27.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,652.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,590.75 | 2019-2022 | |
| Lilly USA, LLC | $1,478.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,051.77 | 2019-2025 | |
| Abbott Laboratories | $1,018.32 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mannkind Corporation | $1,005.50 | 2019-2025 | Afrezza |
| Insulet Corporation | $870.43 | 2019-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $857.70 | 2019-2025 | Jardiance |
| Medtronic, INC. | $794.21 | 2021-2025 | Minimed 780g, Minimed 770g |
| Abbvie INC. | $779.42 | 2019-2025 | |
| Dexcom, INC. | $725.28 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $688.79 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Lifescan, INC. | $555.00 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $427.82 | 2022-2025 | |
| Becton, Dickinson and Company | $406.41 | 2019-2022 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $360.61 | 2019-2025 | Tepezza, Repatha, Repatha |
| Medtronic Minimed, INC. | $319.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $317.88 | 2019-2022 | |
| Antares Pharma, INC. | $307.80 | 2019-2025 | Xyosted |
| Corcept Therapeutics | $240.23 | 2025 | Korlym |
| Amarin Pharma, INC. | $194.00 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $158.78 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $139.00 | 2021-2023 | Tepezza |
| Verity Pharmaceuticals INC. | $125.96 | 2024-2025 | Tlando |
| Sequel Med Tech, LLC | $111.62 | 2025 | Twiist |
| Cequr Corporation | $93.61 | 2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $88.47 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $76.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $75.42 | 2022-2024 | |
| Beta Bionics, INC. | $73.39 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astellas Pharma US INC | $69.32 | 2025 | Veozah |
| Currax Pharmaceuticals LLC | $67.38 | 2019-2021 | |
| Esperion Therapeutics, INC. | $51.08 | 2024-2025 | Nexletol |
| Acella Pharmaceuticals, LLC | $49.27 | 2023-2025 | NP Thyroid 60 |
| Tolmar, INC. | $48.79 | 2023-2025 | Jatenzo |
| Madrigal Pharmaceuticals | $48.66 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $48.31 | 2023-2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $45.45 | 2022-2025 | Unithroid |
| Rhythm Pharmaceuticals, INC. | $34.25 | 2025 | Imcivree |
| Embecta Corp. | $29.55 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Nevro Corp. | $29.12 | 2024 | Senza |
| Senseonics, Incorporated | $26.00 | 2019 | |
| Exact Sciences Corporation | $22.64 | 2024 | Cologuard Collection Kit |
| Intuity Medical INC | $20.91 | 2022 | |
| Vivus LLC | $19.63 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $18.98 | 2025 | |
| Grt US Holding, INC. | $18.18 | 2021 | |
| Clarus Therapeutics INC. | $16.91 | 2021 | |
| Recordati_rare_diseases_inc. | $16.02 | 2025 | Isturisa |
| Roche Diabetes Care, INC. | $15.24 | 2020 | |
| Ascensia Diabetes Care US INC. | $14.28 | 2024 | |
| Nalpropion Pharmaceuticals LLC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.